Our data could avoid the loss of this drug for the future and suggest the need for well-designed studies, such as the evaluation of specific subgroups in terms of IFN levels or clinical factors, for using drugs with complex mechanisms of action in new diseases such as COVID-19. This evidence concerns the gene IFNA1 and COVID-19.